Brief: Abbisko Cayman Says US FDA Grants Rare Pediatric Disease Designation For FGFR2/3 Inhibitor ABSK061
11/03/2026 24:49
March 11 (Reuters) - Abbisko Cayman Ltd 2256.HK: US FDA GRANTS RARE PEDIATRIC DISEASE DESIGNATION FOR FGFR2/3 INHIBITOR ABSK061 Further company coverage: 2256.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly